- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06263478
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After at Least 2 Lines of Systemic Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Incyte Biosciences Japan G.K. Medical Information Center
- Phone Number: 81-120-094-139
- Email: jpmedinfo@incyte.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 6 years of age at the time of signing the ICF.
Ability to comprehend and willingness to sign a written ICF for the study.
• For participants 6 to 17 years old, a parent/guardian must provide consent for pediatric participants; when applicable, pediatric participants should also sign an assent form.
Japanese participants who are allo-HSCT recipients with active, refractory, or recurrent cGVHD requiring systemic immune suppression despite at least 2 lines of prior systemic therapy.
- Active cGVHD is defined as the presence of signs and symptoms of cGVHD per the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
Refractory disease is defined as meeting any of the following criteria:
- The development of 1 or more new sites of disease while being treated for cGVHD.
- Progression of existing sites of disease despite at least 1 month of standard or investigational therapy for cGVHD.
- Participants who did not achieve a response within 3 months on prior therapy for cGVHD and for whom the treating physician believes a new systemic therapy is required.
- Recurrent cGVHD is defined as active, symptomatic disease (after an initial response to prior therapy) based on the NIH 2014 consensus criteria by organ-specific or global assessment or for which the physician believes a new line of systemic therapy is required.
- Participants may have persistent, active aGVHD and cGVHD manifestations (overlap syndrome), as defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
- Karnofsky performance score of ≥ 60 (if aged 16 years or older); Lansky performance score of ≥ 60 (if aged younger than 16 years).
- Adequate organ and bone marrow functions evaluated during the 14 days prior to the start of study treatment.
- Creatinine clearance ≥ 30 mL/min/1.73 m2 based on the Cockcroft-Gault formula in adult participants and Schwartz formula in pediatric participants.
- Concomitant use of a systemic corticosteroid is allowed but not required. Topical and inhaled corticosteroid agents are allowed. If a participant is taking a corticosteroid, it must be a stable dose for at least 2 weeks prior to the start of study treatment.
- Concomitant use of protocol-defined immunosuppressant is allowed but not required.
- Willingness to avoid pregnancy or fathering children based on protocol-defined criteria.
Exclusion Criteria:
- Has aGVHD without manifestations of cGVHD.
- Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
- History of acute or chronic pancreatitis.
- History of myositis.
- History or other evidence of severe illness, uncontrolled infection, allergy to excipients, or any other conditions that would make the participant, in the opinion of the investigator, unsuitable for the study.
- Has acquired immunodeficiency syndrome.
- History of latent or active TB based on protocol-defined criteria.
- Active HBV or HCV infection that requires treatment, or at risk for HBV reactivation (ie, positive HBsAg).
- Pregnant or breastfeeding.
- Previous exposure to CSF-1R targeted therapies.
- Use of any agent other than corticosteroids, or the immunosuppressant for the treatment of cGVHD within 2 weeks or 5 half-lives, whichever is shorter, prior to the start of study treatment.
- Has received an investigational treatment within 28 days prior to the start of study treatment.
- Currently participating in any other interventional study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Axatilimab Dose
Axatilimab at the protocol-defined dose.
|
IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate in the First 6 Cycles
Time Frame: Up to Cycle 7 (Day 169)
|
The overall response rate will be assessed by the number of participants with objective response by Cycle 7 (28-day cycles), Day 1, with responses defined by the 2014 NIH consensus criteria.
|
Up to Cycle 7 (Day 169)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with a ≥ 7-point improvement in modified Lee symptom scale (mLSS) score
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Overall Response Rate
Time Frame: Up to 2 years
|
Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
|
Up to 2 years
|
Duration of Response
Time Frame: Up to 2 years
|
Defined as the time from initial partial response or complete response until documented progression of cGVHD, start of new therapy, or death for any reason.
|
Up to 2 years
|
Organ-specific Response Rate
Time Frame: Up to 2 years
|
Organ-specific response is defined as the number of participants with objective response for the nine individual organs based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (skin, eyes, mouth, esophagus, upper gastrointestinal [GI], lower GI, liver, lungs and joints and fascia).
|
Up to 2 years
|
Percent reduction in average daily dose (or equivalent) of corticosteroids
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Proportion of participants who discontinue corticosteroid use
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to 2 years and 30 days
|
Defined as adverse events reported for the first time or worsening of a pre-existing event from the time the participant signs the informed consent form (ICF) until at least 30 days after the end of trial (EOT) or until start of new cGVHD therapy.
|
Up to 2 years and 30 days
|
Change from baseline in Karnofsky/Lansky performance status
Time Frame: Up to 2 years and 30 days
|
Up to 2 years and 30 days
|
|
Axatilimab pharmacokinetic (PK) in Plasma
Time Frame: Up to 2 years and 30 days
|
Axatilimab concentration in plasma.
|
Up to 2 years and 30 days
|
Number of Participants with Anti-Drug Antibody (ADA)
Time Frame: Up to 2 years and 30 days
|
Up to 2 years and 30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Incyte Medical Monitor, Incyte Corporation
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INCA34176-358
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Graft-versus-host-disease
-
University of LiegeTerminatedChronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host DiseaseBelgium
-
Grupo Espanol de trasplantes hematopoyeticos y...CompletedChronic Graft-Versus-Host DiseaseSpain
-
Hospital Universitario Dr. Jose E. GonzalezRecruitingChronic Graft-versus-host-diseaseMexico
-
Shanghai General Hospital, Shanghai Jiao Tong University...Terminated
-
Universitätsklinikum Hamburg-EppendorfNovartis; Crolll GmbhCompletedChronic Graft-versus-host DiseaseGermany
-
Brigham and Women's HospitalMassachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess... and other collaboratorsCompletedOral Chronic Graft-versus-host DiseaseUnited States
-
Gruppo Italiano Trapianto di Midollo OsseoCompletedChronic Graft-Versus-Host DiseaseItaly
-
MedsenicCompletedImmune System Diseases | Chronic Graft-Versus-Host Disease
-
SCRI Development Innovations, LLCNovartisWithdrawnChronic Graft-Versus-Host DiseaseUnited States
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Sun Yat-sen University; Xinqiao Hospital...Recruiting